This guide is based on Weight & Measure’s conversation about why GLP-1 medications are more than “skinny shots,” emerging retatrutide research and the broader future of obesity and cardiometabolic care.
- Why are GLP-1 medications more than weight-loss shots?
- What is CKM health?
- How does retatrutide fit into emerging research?
- Why might obesity treatment become more individualized?
Why is “skinny shot” an incomplete description?
The conversation argues that reducing obesity medications to cosmetic weight loss misses the chronic disease being treated and the broader health outcomes researchers and clinicians are studying.
What does CKM mean in this conversation?
Cardiovascular, kidney and metabolic health are interconnected. The episode uses that broader frame to discuss why obesity treatment may be evaluated through health outcomes in addition to pounds lost.
Where does retatrutide fit?
Retatrutide is discussed as an investigational therapy in a rapidly changing research landscape. The episode explicitly cautions that enthusiasm about future treatments should not blur the distinction between clinical research and approved care.
What might change in the next era of obesity care?
The guests discuss a future with more treatment options, combination approaches and greater attention to matching treatment to the individual rather than treating one medication or one weight target as the answer for everyone.
GO DEEPER
Listen to the Weight & Measure conversation
GLP-1s Aren't "Skinny Shots": Retatrutide, CKM & the Future of Obesity Care
GLP-1 medications have become some of the most talked about drugs in medicine—but are they really just "skinny shots"?In this episode of Weight & Measure with Mike and Zach, we sit down with two of the most respected vo…
Explore the episode